Telitacicept for IgA Nephropathy
Trial Summary
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications. However, it mentions that participants should have stabilized medications for blood pressure, like AEI/ARB or diuretics, which suggests you may need to continue those.
What data supports the effectiveness of the drug Telitacicept for IgA Nephropathy?
Is Telitacicept safe for humans?
How is the drug telitacicept different from other treatments for IgA nephropathy?
What is the purpose of this trial?
This trial tests an injectable medication called Telitacicept on patients with a kidney disease known as IgA nephropathy. The medication aims to help by adjusting the immune system to reduce kidney damage.
Eligibility Criteria
Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Double-blind Treatment
Participants receive either Telitacicept 160 mg, Telitacicept 240 mg, or placebo subcutaneous injection once weekly for 24 weeks
Follow-up
Participants are monitored for safety and effectiveness after treatment
Open-label Extension (optional)
Participants may opt into continuation of treatment long-term
Treatment Details
Interventions
- Telitacicept
Telitacicept is already approved in China for the following indications:
- Systemic lupus erythematosus (SLE)
Find a Clinic Near You
Who Is Running the Clinical Trial?
RemeGen Co., Ltd.
Lead Sponsor
Dr. Jianmin Fang
RemeGen Co., Ltd.
Chief Executive Officer since 2008
PhD in Molecular Biology
Dr. Ruyi He
RemeGen Co., Ltd.
Chief Medical Officer since 2023
MD